Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Am J Transplant ; 17(3): 791-795, 2017 03.
Article in English | MEDLINE | ID: mdl-27629942

ABSTRACT

Public health concerns exist surrounding the epidemic of the Zika virus (ZIKV) and the rapid growth of transplantation in developing countries, including endemic zones of active arbovirus transmission, as well as travel to such regions by potential organ donors and recipients. Few data exist regarding the clinical characteristics of ZIKV infection in immunocompromised hosts. Laboratory screening protocols for transplantation to differentiate ZIKV infections from other endemic viral diseases and for the detection of possible donor-derived infection have not been stated. The diagnosis of ZIKV infection remains a challenge, fueled by the lack of standardized commercially available diagnostic tests and validated reference diagnostic laboratories, as well as the limited duration of ZIKV viremia. In this small series, ZIKV infection in renal and liver recipients presented without rash, conjunctivitis, or neurological symptoms, and with abnormal graft function, thrombocytopenia, and bacterial superinfection. We report the first case series of ZIKV infection in solid organ recipients, with a description of clinical and laboratory features and therapeutic management.


Subject(s)
Graft Rejection/etiology , Organ Transplantation/adverse effects , Viremia/etiology , Zika Virus Infection/complications , Zika Virus/pathogenicity , Graft Rejection/diagnosis , Graft Survival , Humans , Male , Middle Aged , Prognosis , RNA, Viral/genetics , Risk Factors , Viremia/diagnosis , Zika Virus/genetics , Zika Virus Infection/virology
2.
Antiviral Res ; 174: 104670, 2020 02.
Article in English | MEDLINE | ID: mdl-31812638

ABSTRACT

The GloPID-R (Global Research Collaboration for Infectious Disease Preparedness) chikungunya (CHIKV), o'nyong-nyong (ONNV) and Mayaro virus (MAYV) Working Group has been established to investigate natural history, epidemiology and clinical aspects of infection by these viruses. Here, we present a report dedicated to entomological aspects of CHIKV, ONNV and MAYV. Recent global expansion of chikungunya virus has been possible because CHIKV established a transmission cycle in urban settings using anthropophilic vectors such as Aedes albopictus and Aedes aegypti. MAYV and ONNV have a more limited geographic distribution, being confined to Africa (ONNV) and central-southern America (MAYV). ONNV is probably maintained through an enzootic cycle that has not been characterized yet, with Anopheles species as main vectors and humans as amplification hosts during epidemics. MAYV is transmitted by Haemagogus species in an enzootic cycle using non-human primates as the main amplification and maintenance hosts, and humans becoming sporadically infected when venturing in or nearby forest habitats. Here, we focused on the transmission cycle and natural vectors that sustain circulation of these viruses in their respective locations. The knowledge of the natural ecology of transmission and the capacity of different vectors to transmit these viruses is crucial to understand CHIKV emergence, and to assess the risk that MAYV and ONNV will expand on wide scale using anthropophilic mosquito species not normally considered primary vectors. Finally, the experts identified knowledge gaps and provided adapted recommendations, in order to address future entomological investigations in the right direction.


Subject(s)
Alphavirus Infections/transmission , Chikungunya Fever/transmission , Mosquito Vectors/virology , Aedes/virology , Africa , Animals , Anopheles/virology , Central America , Chikungunya virus/pathogenicity , Humans , O'nyong-nyong Virus/pathogenicity , Primates/virology , Research Report
3.
Antiviral Res ; 172: 104611, 2019 12.
Article in English | MEDLINE | ID: mdl-31545982

ABSTRACT

The GloPID-R (Global Research Collaboration for Infectious Disease Preparedness) chikungunya (CHIKV), o'nyong-nyong (ONNV) and Mayaro virus (MAYV) Working Group has been established to identify gaps of knowledge about the natural history, epidemiology and medical management of infection by these viruses, and to provide adapted recommendations for future investigations. Here, we present a report dedicated to ONNV epidemiological distribution. Two large-scale ONNV outbreaks have been identified in Africa in the last 60 years, interspersed with sporadic serosurveys and case reports of returning travelers. The assessment of the real scale of ONNV circulation in Africa remains a difficult task and surveillance studies are necessary to fill this gap. The identification of ONNV etiology is made complicated by the absence of multiplex tools in co-circulation areas and that of reference standards, as well as the high cross-reactivity with related pathogens observed in serological tests, in particular with CHIKV. This is a specific obstacle for seroprevalence studies, that necessitate an improvement of serological tools to provide robust results. The scarcity of existent genetic data currently limits molecular epidemiology studies. ONNV epidemiology would also benefit from reinforced entomological and environmental surveillance. Finally, the natural history of the disease deserves to be further investigated, with a specific attention paid to long-term complications. Considering our incomplete knowledge on ONNV distribution, GloPID-R CHIKV, ONNV and MAYV experts recommend that a major effort should be done to fill existing gaps.


Subject(s)
Alphavirus Infections , Alphavirus , O'nyong-nyong Virus , Africa/epidemiology , Alphavirus/genetics , Alphavirus/isolation & purification , Alphavirus Infections/diagnosis , Alphavirus Infections/epidemiology , Alphavirus Infections/immunology , Alphavirus Infections/prevention & control , Animals , Chikungunya Fever/epidemiology , Chikungunya virus/immunology , Disease Outbreaks , Genes, Viral , Humans , Iron , O'nyong-nyong Virus/genetics , O'nyong-nyong Virus/isolation & purification , Phylogeny , Seroepidemiologic Studies , Serologic Tests
4.
Antiviral Res ; 166: 66-81, 2019 06.
Article in English | MEDLINE | ID: mdl-30905821

ABSTRACT

The GloPID-R (Global Research Collaboration for Infectious Disease Preparedness) Chikungunya (CHIKV), O'nyong-nyong (ONNV) and Mayaro virus (MAYV) Working Group is investigating the natural history, epidemiology and medical management of infection by these viruses, to identify knowledge gaps and to propose recommendations for direct future investigations and rectification measures. Here, we present the first report dedicated to diagnostic aspects of CHIKV, ONNV and MAYV. Regarding diagnosis of the disease at the acute phase, molecular assays previously described for the three viruses require further evaluation, standardized protocols and the availability of international standards representing the genetic diversity of the viruses. Detection of specific IgM would benefit from further investigations to clarify the extent of cross-reactivity among the three viruses, the sensitivity of the assays, and the possible interfering role of cryoglobulinaemia. Implementation of reference panels and external quality assessments for both molecular and serological assays is necessary. Regarding sero-epidemiological studies, there is no reported high-throughput assay that can distinguish among these different viruses in areas of potential co-circulation. New specific tools and/or improved standardized protocols are needed to enable large-scale epidemiological studies of public health relevance to be performed. Considering the high risk of future CHIKV, MAYV and ONNV outbreaks, the Working Group recommends that a major investigation should be initiated to fill the existing diagnostic gaps.


Subject(s)
Alphavirus Infections/diagnosis , Chikungunya Fever/diagnosis , Communicable Diseases, Emerging/diagnosis , Alphavirus/genetics , Alphavirus/immunology , Alphavirus/isolation & purification , Alphavirus Infections/epidemiology , Animals , Antibodies, Viral , Chikungunya virus/genetics , Chikungunya virus/immunology , Chikungunya virus/isolation & purification , Communicable Diseases, Emerging/epidemiology , Cross Reactions , Cryoglobulinemia/virology , Genes, Viral , Humans , Mosquito Vectors/virology , O'nyong-nyong Virus/genetics , O'nyong-nyong Virus/immunology , O'nyong-nyong Virus/isolation & purification , Pathology, Molecular , Phylogeny , Seroepidemiologic Studies
5.
Clin Microbiol Infect ; 24(6): 646-652, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29133154

ABSTRACT

OBJECTIVES: We aimed to report the first 54 cases of pregnant women infected by Zika virus (ZIKV) and their virologic and clinical outcomes, as well as their newborns' outcomes, in 2016, after the emergence of ZIKV in dengue-endemic areas of São Paulo, Brazil. METHODS: This descriptive study was performed from February to October 2016 on 54 quantitative real-time PCR ZIKV-positive pregnant women identified by the public health authority of São José do Rio Preto, São Paulo, Brazil. The women were followed and had clinical and epidemiologic data collected before and after birth. Adverse outcomes in newborns were analysed and reported. Urine or blood samples from newborns were collected to identify ZIKV infection by reverse transcription PCR (RT-PCR). RESULTS: A total of 216 acute Zika-suspected pregnant women were identified, and 54 had the diagnosis confirmed by RT-PCR. None of the 54 women miscarried. Among the 54 newborns, 15 exhibited adverse outcomes at birth. The highest number of ZIKV infections occurred during the second and third trimesters. No cases of microcephaly were reported, though a broad clinical spectrum of outcomes, including lenticulostriate vasculopathy, subependymal cysts, and auditory and ophthalmologic disorders, were identified. ZIKV RNA was detected in 18 of 51 newborns tested and in eight of 15 newborns with adverse outcomes. CONCLUSIONS: Although other studies have associated many newborn outcomes to ZIKV infection during pregnancy, these same adverse outcomes were rare or nonexistent in this study. The clinical presentation the newborns we studied was mild compared to other reports, suggesting that there is significant heterogeneity in congenital Zika infection.


Subject(s)
Fetal Diseases/virology , Pregnancy Complications, Infectious/virology , Zika Virus Infection/complications , Zika Virus/isolation & purification , Adult , Brazil , Female , Humans , Infant, Newborn , Phylogeny , Pregnancy , Young Adult , Zika Virus/classification , Zika Virus/genetics
7.
Digestion ; 73(4): 259-64, 2006.
Article in English | MEDLINE | ID: mdl-16940728

ABSTRACT

BACKGROUND/AIM: Hypertriglyceridemia is rare and can provoke acute severe hyperlipidemic pancreatitis when triglyceride levels exceed 11.3 mmol/l. In 10 patients we evaluated the therapeutic guidelines for severe hyperlipidemic pancreatitis. METHODS: Ten patients (8 men and 2 women) were admitted to the intensive care unit with a diagnosis of acute severe hyperlipidemic pancreatitis. They underwent standard treatment. Heparin, insulin and antihyperlipidemic drugs were used to lower the triglyceride levels. The patients underwent plasmapheresis within 48 h of admission, and fat-free parenteral nutrition was used. Two of the patients underwent surgery because of infection of necrotic segments. RESULTS: Standard treatment was essential for all the patients but plasmapheresis was the procedure that lowered the triglyceride and lipid levels in all cases. It improved abdominal pain, clinical state, and signs and symptoms of the disease. Two patients underwent surgery due to infection of the necrotic segments and one of them died. Follow-up lasted 4-54 months with no recurrences of pancreatitis. CONCLUSION: Our study shows that standard treatment is essential, but plasmapheresis successfully lowered lipid levels with no complications and relieved the patients from the symptoms in the acute phase of the disease. Hyperlipidemic pancreatitis should initially be treated conservatively. Plasmapheresis is a method that has lately been used successfully for hyperlipidemic pancreatitis. It seems that all therapeutic measures should be applied as early as possible, within the first 48 h.


Subject(s)
Anticholesteremic Agents/adverse effects , Hyperlipidemias/complications , Pancreatitis, Acute Necrotizing/therapy , Parenteral Nutrition/methods , Plasmapheresis/methods , Adult , Aged , Anticholesteremic Agents/therapeutic use , Female , Follow-Up Studies , Humans , Hyperlipidemias/blood , Hyperlipidemias/drug therapy , Male , Middle Aged , Pancreatitis, Acute Necrotizing/blood , Pancreatitis, Acute Necrotizing/chemically induced , Retrospective Studies , Treatment Outcome , Triglycerides/blood
8.
J Virol ; 75(9): 4048-55, 2001 May.
Article in English | MEDLINE | ID: mdl-11287554

ABSTRACT

The B1 gene of vaccinia virus encodes a serine/threonine protein kinase that is expressed early after infection. Under nonpermissive conditions, temperature-sensitive mutants (ts2 and ts25) that map to B1 fail to efficiently replicate viral DNA. Our goal was to extend studies on the function of B1 by determining if the kinase is required for intermediate or late gene expression, two events that ordinarily depend on viral DNA replication. First, we established that early viral gene expression occurred at the nonpermissive temperature. By using a transfection procedure that circumvents the viral DNA replication requirement, we found that reporter genes regulated by an intermediate promoter were transcribed only under conditions permissive for expression of active B1. To assay late gene expression, the T7 RNA polymerase gene was inserted into the genome of ts25 to form ts25/T7. A DNA replication-independent late gene transcription system was established by cotransfecting plasmids containing T7 promoter-driven late gene transcription factors and a late promoter reporter gene into ts25/T7-infected cells. Late genes, unlike intermediate genes, were expressed at the nonpermissive temperature. Last, we showed that overexpression of B1 stimulated intermediate but inhibited late gene expression in cells infected with wild-type virus.


Subject(s)
Gene Expression Regulation, Viral , Genes, Immediate-Early , Genes, Viral , Protein Serine-Threonine Kinases/physiology , Vaccinia virus/enzymology , Viral Proteins/physiology , Animals , Cell Line , Chlorocebus aethiops , DNA-Directed RNA Polymerases/genetics , Immediate-Early Proteins/biosynthesis , L Cells , Mice , Protein Serine-Threonine Kinases/genetics , Transcription, Genetic , Vaccinia virus/genetics , Viral Proteins/biosynthesis , Viral Proteins/genetics
SELECTION OF CITATIONS
SEARCH DETAIL